Skip to content

Ophthalmology

Study findings updated . AI-assisted evidence summary, not individual medical advice or a clinician endorsement.

Key findings

1 in 7 died14% mortality at final follow-up in COVID-linked black fungus of nose and eye

1 in 7 Indian patients with COVID-linked black fungus died.

Among people in India with COVID-19-linked mucormycosis ('black fungus') spreading from the nose and sinuses toward the eye socket and brain, 14% had died by final follow-up. 87% had been given corticosteroid (steroid) drugs for COVID-19, and most had diabetes. Surgeons removed the eye and eye-socket contents in 15%, and did so along with sinus surgery in 17%.

Diabetes plus steroid treatment emerged as the dangerous mix. This fungus can take an eye or a life, so new face or eye pain, swelling or vision loss during or after COVID-19 needs urgent care. A retrospective review of treated cases with no comparison group, so it describes who was affected rather than measuring how much each factor raised risk.

See the evidence

A retrospective multicenter review of 2,826 patients with COVID-19-associated rhino-orbital-cerebral mucormycosis treated at 102 centers across India, January 2020 to May 2021.

From the study: “At final follow-up, mortality was 14%.”

1 in 7 died

Sen M et al. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India - Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1. Indian journal of ophthalmology. 2021.

From the study: “87% of the patients were treated with corticosteroids”

1 in 7 died

Sen M et al. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India - Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1. Indian journal of ophthalmology. 2021.

From the study: “orbital exenteration in 15%, and both FESS/PNS debridement and orbital exenteration in 17%”

1 in 7 died

Sen M et al. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India - Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1. Indian journal of ophthalmology. 2021.

About 1 in 9 patientsFrom a pooled 11.03% of COVID-19 patients with at least one eye symptom

About 1 in 9 COVID-19 patients had at least one eye symptom.

A review covering 8,219 COVID-19 patients estimated that 11.03% had at least one eye symptom, most often dryness or a gritty feeling, redness, tearing, itching, eye pain or discharge. Among specific eye diseases reported, conjunctivitis (pink eye) made up 88.8% (79 of 89).

Red, watery or gritty eyes can be part of COVID-19 itself, so new pink eye during a wave of infections can be a reason to consider a COVID-19 test. Pooled estimate from mostly small hospital studies found in searches through August 2020, with a wide uncertainty range (5.71% to 17.72%).

See the evidence

A systematic review and meta-analysis of 38 studies with 8,219 COVID-19 patients, mostly hospitalized, from searches through August 2020.

From the study: “The prevalence of ocular manifestations was estimated to be 11.03% (95% CI: 5.71-17.72).”

About 1 in 9 patients

Nasiri N et al. Ocular Manifestations of COVID-19: A Systematic Review and Meta-analysis. Journal of ophthalmic & vision research. 2021.

From the study: “Moreover, conjunctivitis had the highest rate among reported ocular diseases in COVID-19 patients (79 out of 89, 88.8%).”

About 1 in 9 patients

Nasiri N et al. Ocular Manifestations of COVID-19: A Systematic Review and Meta-analysis. Journal of ophthalmic & vision research. 2021.

From the study: “Thirty-eight studies were eligible after screening of 895 unique articles, with a total of 8,219 COVID-19 patients”

About 1 in 9 patients

Nasiri N et al. Ocular Manifestations of COVID-19: A Systematic Review and Meta-analysis. Journal of ophthalmic & vision research. 2021.

No increase in uveitisVaccinated vs matched unvaccinated people: hazard ratio 0.91, not significant

Researchers found no overall uveitis rise after COVID-19 vaccination, except ages 5–44.

In US insurance records, vaccinated people were compared with matched unvaccinated people from before vaccines existed. New uveitis (inflammation inside the eye, not from infection) was not more common after vaccination (hazard ratio 0.91). A within-person check also found no overall rise (1.05), but people aged 5 to 44 had a 40% higher rate after vaccination (rate ratio 1.40).

For most people, COVID-19 vaccination did not raise the chance of this eye inflammation. The signal in younger people may reflect stronger immune responses and is still being investigated. Observational claims study relying on billing codes; the younger-age signal came from a subgroup of a 686-patient within-person analysis and needs confirmation.

See the evidence

A US OptumLabs insurance-claims study of people without prior uveitis vaccinated December 2020 to November 2021, with about 4.6 million in a matched comparison and 686 in a within-person analysis.

From the study: “The adjusted HR comparing NIU incidence in the COVID-19-vaccinated and unvaccinated cohort was 0.91”

No increase in uveitis

Kumar A et al. Risk of Noninfectious Uveitis after Coronavirus Disease 2019 Vaccination in a United States Claims Database. Ophthalmology. 2023.

From the study: “The IRR comparing NIU risk after vaccination with risk during control intervals was 1.05”

No increase in uveitis

Kumar A et al. Risk of Noninfectious Uveitis after Coronavirus Disease 2019 Vaccination in a United States Claims Database. Ophthalmology. 2023.

From the study: “An increased risk was found in the subgroup aged 5 to 44 years (IRR, 1.40; 95% CI, 1.04-1.87; P = 0.024).”

No increase in uveitis

Kumar A et al. Risk of Noninfectious Uveitis after Coronavirus Disease 2019 Vaccination in a United States Claims Database. Ophthalmology. 2023.

13% below expectedAverage shortfall per eye diagnosis, mid-2020 to end-2021; it hit 67% in spring 2020

US eye-care visits stayed below expected levels through 2021 for most conditions.

In records of 44.62 million US eye patients, the number seen per eye condition averaged 67% below what pre-pandemic trends predicted at the early-pandemic low, and 13% below afterward. Visits for 94.3% of diagnoses stayed below normal, including early stages of macular degeneration, diabetic eye disease, cataract and glaucoma. Less severe conditions saw the biggest drops.

Many skipped visits were for early, symptom-free stages of blinding diseases, when care can still protect sight. A backlog of missed checkups may show up later as vision that could have been saved. Compares observed patient counts with model predictions in one US registry; it shows who was seen, not whether anyone lost vision as a result.

See the evidence

An analysis of a US eye-care registry covering 44.62 million patients at 2,455 practices, comparing January 2020 to December 2021 volumes for 261 diagnoses with pre-pandemic predictions.

From the study: “Mean deviations among all diagnoses are 67% below expectation during the hiatus peak, and 13% post-hiatus.”

13% below expected

Li C et al. Shifts in ophthalmic care utilization during the COVID-19 pandemic in the US. Communications medicine. 2023.

From the study: “Records from 44.62 million patients and 2455 practices show lasting reductions in ophthalmic care utilization, including visits for leading causes of visual impairment”

13% below expected

Li C et al. Shifts in ophthalmic care utilization during the COVID-19 pandemic in the US. Communications medicine. 2023.

From the study: “despite a rebound, utilization mostly (for 94.3% of diagnoses) remain below pre-pandemic volumes in the post-hiatus period”

13% below expected

Li C et al. Shifts in ophthalmic care utilization during the COVID-19 pandemic in the US. Communications medicine. 2023.

3,717 adults, no benefitRegistry-confirmed COVID-19: 3.7% wearing glasses vs 3.5% not, randomized trial

Wearing glasses in public did not measurably cut confirmed COVID-19 infections.

In a Norwegian trial, adults who don't usually wear glasses were randomly assigned to wear glasses or sunglasses near others in public, or not. Registry-reported positive COVID-19 tests were 3.7% with glasses and 3.5% without. Self-reported respiratory infections were somewhat lower with glasses (30.8% vs 34.1%), a hint the authors say needs more trials.

The eyes are a possible entry route for the virus, but this first randomized test of everyday glasses found no clear drop in confirmed infections. Glasses remain, at best, an unproven extra layer. The trial fell far short of its recruitment target and Norway changed testing rules during it, so the result is imprecise and compatible with benefit or harm.

See the evidence

A randomized trial of 3,717 adults in Norway, February to April 2022, asked to wear or not wear glasses (such as sunglasses) near others in public for 2 weeks.

From the study: “The proportions with a reported positive COVID-19 test result in the national registry were 3.7% (68 of 1852) in the intervention group and 3.5% (65 of 1865) in the control group”

3,717 adults, no benefit

Fretheim A et al. Effect of Wearing Glasses on Risk of Infection With SARS-CoV-2 in the Community: A Randomized Clinical Trial. JAMA network open. 2022.

From the study: “The risk of respiratory infections based on self-reported symptoms was lower in the intervention group (30.8% [571 of 1852]) than in the control group (34.1% [636 of 1865]”

3,717 adults, no benefit

Fretheim A et al. Effect of Wearing Glasses on Risk of Infection With SARS-CoV-2 in the Community: A Randomized Clinical Trial. JAMA network open. 2022.

From the study: “A total of 3717 adults (2439 women [65.6%]; mean [SD] age, 46.9 [15.1] years) were randomized.”

3,717 adults, no benefit

Fretheim A et al. Effect of Wearing Glasses on Risk of Infection With SARS-CoV-2 in the Community: A Randomized Clinical Trial. JAMA network open. 2022.

No rise in eye strokesFirst mRNA dose vs flu shot: relative risk 0.74, not a significant difference

Eye strokes after mRNA COVID-19 vaccines were rare, similar to flu-shot rates.

In a large US health-records network, 0.003% of people given an mRNA COVID-19 vaccine had a new retinal vascular occlusion (a blocked retinal blood vessel, or 'eye stroke') diagnosed within 21 days. After a first dose, the rate was not significantly different from after a flu shot (relative risk 0.74) or a Tdap shot. It was higher after the first dose than after the second (relative risk 2.25).

Eye strokes after vaccination were extremely rare and no more frequent than after long-used vaccines, which speaks to a worry raised by earlier case reports about mRNA shots. Observational records study that compared vaccines with one another rather than with unvaccinated people, and relied on diagnosis codes.

See the evidence

A US TriNetX health-records analysis of about 3.1 million mRNA COVID-19 vaccine recipients, compared with matched historical flu and Tdap vaccine recipients, run in October 2022.

From the study: “104 (0.003%; 95% CI, 0.003%-0.004%) patients had a new diagnosis of RVO within 21 days of vaccination”

No rise in eye strokes

Dorney I et al. Risk of New Retinal Vascular Occlusion After mRNA COVID-19 Vaccination Within Aggregated Electronic Health Record Data. JAMA ophthalmology. 2023.

From the study: “the RR for new RVO diagnosis after the first dose of COVID-19 vaccination was not significantly different from that after influenza (RR, 0.74; 95% CI, 0.54-1.01)”

No rise in eye strokes

Dorney I et al. Risk of New Retinal Vascular Occlusion After mRNA COVID-19 Vaccination Within Aggregated Electronic Health Record Data. JAMA ophthalmology. 2023.

From the study: “but was greater when compared with the second dose of the COVID-19 vaccination (RR, 2.25; 95% CI, 1.33-3.81).”

No rise in eye strokes

Dorney I et al. Risk of New Retinal Vascular Occlusion After mRNA COVID-19 Vaccination Within Aggregated Electronic Health Record Data. JAMA ophthalmology. 2023.

40% higher oddsOdds of myopia in kids examined during vs before the pandemic (odds ratio 1.40)

Hong Kong children's myopia kept rising after COVID-19 restrictions were lifted.

In Hong Kong's young schoolchildren, myopia (nearsightedness) held at 23.5%-24.9% from 2015 to 2019, rose to 28.8% in 2020 and reached 36.2% in 2021, after restrictions ended. Pandemic-era exams were linked to 40% higher odds of myopia. Daily time outdoors fell to 0.85 hours in 2020 and was still just 1.26 hours in 2021; lower-income children had more screen time.

The pandemic's effect on children's eyes did not simply reverse when schools reopened, because less outdoor time and more screen time lingered. Younger and lower-income children appear most exposed. Repeated cross-sectional surveys of different children each year, with lifestyle from questionnaires, so it shows a trend rather than proof that restrictions caused myopia.

See the evidence

The population-based Hong Kong Children Eye Study, which examined 20,527 children aged 6 to 8 with eye-dilating drops between 2015 and 2021.

From the study: “myopia prevalence was stable from 2015 to 2019 (23.5%-24.9%; P = .90) but increased to 28.8% (P < .001) in 2020 and 36.2% (P < .001) in 2021.”

40% higher odds

Zhang XJ et al. Prevalence of Myopia in Children Before, During, and After COVID-19 Restrictions in Hong Kong. JAMA network open. 2023.

From the study: “High myopia prevalence was associated with the COVID-19 pandemic (odds ratio [OR], 1.40; 95% CI, 1.28-1.54; P < .001)”

40% higher odds

Zhang XJ et al. Prevalence of Myopia in Children Before, During, and After COVID-19 Restrictions in Hong Kong. JAMA network open. 2023.

From the study: “The mean (SD) time spent outdoors was much lower in 2020 (0.85 [0.53] h/d; P < .001) and 2021 (1.26 [0.48] h/d; P < .001) compared with pre-COVID-19 levels (1.40 [0.47]-1.46 [0.65] h/d).”

40% higher odds

Zhang XJ et al. Prevalence of Myopia in Children Before, During, and After COVID-19 Restrictions in Hong Kong. JAMA network open. 2023.

19% lower uveitis riskEarly antiviral vs none in matched US COVID-19 patients (hazard ratio 0.81)

Early COVID-19 antivirals were linked to less uveitis, mainly with Paxlovid.

Among US adults with COVID-19, new uveitis (inflammation inside the eye) was diagnosed in 0.089% of those given an antiviral soon after diagnosis versus 0.110% of matched patients not given one, a 19% lower risk. Paxlovid (nirmatrelvir-ritonavir) was linked to lower risk (hazard ratio 0.83); molnupiravir and remdesivir showed no significant effect.

Uveitis was uncommon in both groups, so the absolute difference is small. The result hints that early antiviral treatment might carry an eye benefit, a question for future trials. Observational records study from 2022 to 2024; patients given antivirals may differ in ways matching missed, so it cannot prove the drugs prevented uveitis.

See the evidence

A US TriNetX health-records study of adults with COVID-19 in 2022 to 2024, matching 438,455 who got Paxlovid, molnupiravir or remdesivir within 5 days with 438,455 untreated patients.

From the study: “the cumulative incidence of uveitis was significantly lower in the antiviral group (391 events, 0.089%) compared to the non-antiviral group (479 events, 0.110%)”

19% lower uveitis risk

Kuo HT et al. Impact of Early COVID-19 Antiviral Therapy on the Incidence of Uveitis: A Retrospective Cohort Study Using the TriNetX Database. Immunity, inflammation and disease. 2026.

From the study: “Among the antivirals, Paxlovid was associated with a significant risk reduction (HR = 0.83, 95% CI: 0.71-0.96), whereas Molnupiravir and Remdesivir showed no statistically significant effect.”

19% lower uveitis risk

Kuo HT et al. Impact of Early COVID-19 Antiviral Therapy on the Incidence of Uveitis: A Retrospective Cohort Study Using the TriNetX Database. Immunity, inflammation and disease. 2026.

From the study: “and all duration (HR = 0.81, 95% CI: 0.71-0.93)”

19% lower uveitis risk

Kuo HT et al. Impact of Early COVID-19 Antiviral Therapy on the Incidence of Uveitis: A Retrospective Cohort Study Using the TriNetX Database. Immunity, inflammation and disease. 2026.

Study-specific findings. Different populations, treatments and follow-up periods can produce different results.

Browse all 0 recorded findingsSearch the original results, comparisons and study details.
0 of 0 source groupsFindings stay together with their study.

The research starts here.

No study findings are available in this monitor yet.

Browse the 8 original sourcesThe complete bibliography behind this monitor.
  1. [1]

    Sen M et al. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India - Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1. Indian journal of ophthalmology. 2021.

    Open original source in a new tab
  2. [2]

    Nasiri N et al. Ocular Manifestations of COVID-19: A Systematic Review and Meta-analysis. Journal of ophthalmic & vision research. 2021.

    Open original source in a new tab
  3. [3]

    Kumar A et al. Risk of Noninfectious Uveitis after Coronavirus Disease 2019 Vaccination in a United States Claims Database. Ophthalmology. 2023.

    Open original source in a new tab
  4. [4]

    Li C et al. Shifts in ophthalmic care utilization during the COVID-19 pandemic in the US. Communications medicine. 2023.

    Open original source in a new tab
  5. [5]

    Fretheim A et al. Effect of Wearing Glasses on Risk of Infection With SARS-CoV-2 in the Community: A Randomized Clinical Trial. JAMA network open. 2022.

    Open original source in a new tab
  6. [6]

    Dorney I et al. Risk of New Retinal Vascular Occlusion After mRNA COVID-19 Vaccination Within Aggregated Electronic Health Record Data. JAMA ophthalmology. 2023.

    Open original source in a new tab
  7. [7]

    Zhang XJ et al. Prevalence of Myopia in Children Before, During, and After COVID-19 Restrictions in Hong Kong. JAMA network open. 2023.

    Open original source in a new tab
  8. [8]

    Kuo HT et al. Impact of Early COVID-19 Antiviral Therapy on the Incidence of Uveitis: A Retrospective Cohort Study Using the TriNetX Database. Immunity, inflammation and disease. 2026.

    Open original source in a new tab

About this collection.

Read each original paper for its complete methods, population and limitations. Different studies can ask different questions and report different kinds of results. Dates marked “added” describe when a finding entered this monitor, not when the study was published or clinically reviewed.

Download and methodology

Download the findings and bibliography displayed in this page snapshot. Values and confidence intervals remain as reported text; this is not a pooled estimate or a systematic review. Product-label observations and editorial takeaways are excluded.

These findings may omit evidence or contain errors and have not been reviewed by a clinician. A citation or download does not establish source verification. Read the original studies for their methods and limitations.

The October 2026 COVID citation audit found errors in this collection. These downloads may still contain affected findings and bibliography entries. Read the correction record before using them.

“Added” dates record entry into the monitor, not publication or clinical review. A null original acquisition or derivation means its historical record is unknown; a current record or verification has its own observation time. The SHA-256 snapshot identifier binds the downloadable public fields. CSV includes finding rows and bibliography-only source rows; JSON includes both lists. Spreadsheet-sensitive CSV cells begin with an apostrophe for safety; JSON preserves the original text.

For attribution, cite ModernDoc and the page URL, data update date and snapshot identifier in the download. Original studies retain their own rights; this download does not grant a licence to their full text.